Abstract | BACKGROUND AND PURPOSE: MATERIAL AND METHODS: Thirty-nine patients with inextirpable adenocarcinoma of the pancreas, gallbladder or extrahepatic bile ducts were included. Two cycles of XELOX ( capecitabine 1000 mg/m(2) bid d1-14+oxaliplatin 130 mg/m(2) d1, q3w) were followed by XELOX-RT ( radiotherapy (50.4 Gy), combined with capecitabine 750-675 mg/m(2) bid every radiotherapy day and oxaliplatin 40-30 mg/m(2) once weekly). Primary end-points were tolerance (phase I) and objective response (phase II). RESULTS: The maximum tolerated doses of oxaliplatin and capecitabine to combine with irradiation were 30 mg/m(2) and 675 mg/m(2), respectively. Twenty-one percent (95% CI: 9-38%) of evaluable patients achieved partial response. Five patients went through surgery (three R0 resections). Two-year survival was 28%, and estimated local tumour control rate at 2 years was 72%. The most common grade 3-4 toxicity was nausea and vomiting. CONCLUSIONS:
|
Authors | Adalsteinn Gunnlaugsson, Harald Anderson, Pehr Lind, Bengt Glimelius, Anders Johnsson |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 95
Issue 3
Pg. 292-7
(Jun 2010)
ISSN: 1879-0887 [Electronic] Ireland |
PMID | 20451275
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2010. Published by Elsevier Ireland Ltd. |
Chemical References |
- CA-19-9 Antigen
- Organoplatinum Compounds
- Oxaliplatin
- Deoxycytidine
- Capecitabine
- Fluorouracil
|
Topics |
- Adenocarcinoma
(mortality, pathology, therapy)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Biliary Tract Neoplasms
(mortality, pathology, therapy)
- CA-19-9 Antigen
(blood)
- Capecitabine
- Combined Modality Therapy
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Female
- Fluorouracil
(administration & dosage, analogs & derivatives)
- Humans
- Male
- Middle Aged
- Organoplatinum Compounds
(administration & dosage)
- Oxaliplatin
- Pancreatic Neoplasms
(mortality, pathology, therapy)
- Patient Compliance
- Treatment Outcome
|